CClinicalTrials.gg
WithdrawnNCT03521128Updated Sep 24, 2019

Comparing Radiological Tubal Blockage Versus Laparoscopic Salpingectomy in Infertile Women With Hydrosalpinx During in Vitro Fertilization Treatment

An interventional study of radiological tubal blockage and laparoscopic salpingectomy in IVF-ET and Hydrosalpinx, sponsored by ShangHai Ji Ai Genetics & IVF Institute. Withdrawn at 1 site in China. Open to female participants aged 20 Years to 43 Years. Per ClinicalTrials.gov, last updated 2019-09-24.

Sponsored by ShangHai Ji Ai Genetics & IVF Institute · Not applicable, Interventional, and Treatment

Why this study was withdrawn
poor recruitment, no participants enrolled
Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
20 Years to 43 Years
Sex
Female
01

Study summary

Hydrosalpinx (HX) has a detrimental effect on the rates of implantation, pregnancy, live delivery, and early pregnancy loss during in vitro fertilization (IVF). The effectiveness of radiological tubal blockage has not been compared with the standard treatment of laparoscopic salpingectomy in randomized trials. The investigators aim in this randomized trial to compare the live birth rate of radiological tubal blockage versus laparoscopic salpingectomy in infertility women with HX prior to frozen-thawed embryo transfer (FET). Eligible women will be recruited and randomized into one of the following two groups: (1) the radiological tubal blockage group and (2) the laparoscopic salpingectomy group. The primary outcome is the live birth rate.

02

Conditions studied

  • IVF-ET
  • Hydrosalpinx

Browse trials for

03

In context

Infertility

2,506 studies on the registry are indexed under Infertility; 407 are open to participants now.

Browse Infertility studies →

Lead sponsor

ShangHai Ji Ai Genetics & IVF Institute is the lead sponsor of 24 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 43 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • Women aged 20-43 years at the time of IVF/ICSI treatment
  • Unilateral or bilateral HX visible on pelvic ultrasound or hysterosalpingogram
  • At least one frozen embryo or blastocyst available for transfer

Exclusion criteria

Exclusion Criteria:

  • A history of pelvic inflammatory disease within 6 months
  • HX that were already blocked proximally on hysterosalpingogram
  • Frozen pelvis from previous laparoscopy
  • Women with fibroids interfering with radiological tubal blockage
  • Undergoing preimplantation genetic testing
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    the radiological tubal blockage group

    Procedure: radiological tubal blockage

  • Active comparator
    the laparoscopic salpingectomy group

    Procedure: laparoscopic salpingectomy

Interventions

  • Procedureradiological tubal blockage

    In radiological tubal blockage group, under the fluoroscopy of X-ray, after confirming HX by HSG, selective catheterization will be done for the affected tube and micro spring coils will be put in to the interstitial tube and isthmus through micro catheter. The micro spring coil will be placed into the proximal end of the Fallopian tube (unilateral or bilateral depending on whether one or two HX were present) through micro catheter under the fluoroscopy of X-ray. Then HSG will be carried out to check the position of the micro spring coil and confirm complete blockage. Four weeks after the radiological procedure, a HSG will be performed to recheck the position of the micro spring coil and complete blockage of the tubes. FET is proceeded in the next menstrual cycle after HSG examination.

  • Procedurelaparoscopic salpingectomy

    In the laparoscopic salpingectomy group, after confirming HX, a unilateral or bilateral salpingectomy will be performed in a standard manner, depending on whether unilateral or bilateral HX are present. In women with extensive pelvic adhesions during laparoscopy, proximal tubal ligation will be performed as an alternative procedure to salpingectomy. FET is proceeded in the next menstrual cycle after the laparoscopic operation.

06

What researchers measure

Primary outcomes

  1. live birth rate

    the rate of live births per cycle

    Time frame: a live birth after 22 weeks gestation, through study completion, an average of 1 year

Secondary outcomes

  1. positive hCG level

    defined with the result of serum β-hCG ≥10 mIU/mL.

    Time frame: A blood hCG test is performed 14 days after the FET, up to 14 days

  2. clinical pregnancy rate

    presence of intrauterine gestational sac on ultrasound at 6 weeks of pregnancy

    Time frame: presence of intrauterine gestational sac on ultrasound at 6 weeks of pregnancy, up to 6 weeks

  3. ongoing pregnancy rate

    presence of a fetal pole with pulsation at 12 weeks of gestation

    Time frame: iable pregnancy beyond gestation 12 weeks, up to 12 weeks

  4. implantation rate

    number of gestational sacs per embryo transferred

    Time frame: number of gestational sacs per embryo transferred at 6 weeks of pregnancy, up to 6 weeks

  5. multiple pregnancy

    more than one intrauterine sacs on scanning

    Time frame: multiple pregnancy beyond gestation 12 weeks up to 12 weeks

  6. miscarriage rate

    defined as a clinically recognized pregnancy loss before the 22 weeks of pregnancy. The denominator is the clinical pregnancy.

    Time frame: a clinically recognized pregnancy loss before the 22 weeks of pregnancy, up to 22 weeks

  7. ectopic pregnancy

    pregnancy outside the uterine cavity

    Time frame: ectopic pregnancy during first trimester, up to 12 weeks

  8. birth weight

    birth weight of the baby delivered

    Time frame: a live birth after 22 weeks gestation, through study completion, an average of 1 year

07

Study locations

1 site
  • ShangHai JIAI Genetics&IVF Institute
    Shanghai, China
08

References and documents

Publications

  • Aboulghar MA, Mansour RT, Serour GI. Controversies in the modern management of hydrosalpinx. Hum Reprod Update. 1998 Nov-Dec;4(6):882-90. doi: 10.1093/humupd/4.6.882. PubMed 10098478 ↗
  • Camus E, Poncelet C, Goffinet F, Wainer B, Merlet F, Nisand I, Philippe HJ. Pregnancy rates after in-vitro fertilization in cases of tubal infertility with and without hydrosalpinx: a meta-analysis of published comparative studies. Hum Reprod. 1999 May;14(5):1243-9. doi: 10.1093/humrep/14.5.1243. PubMed 10325271 ↗
  • Li Q, Kuang YP, Yang HL, Fu YL, Sun H, Fan LP, Shi HB. [Application of fallopian tube embolization before in vitro fertilization and embryo transfer dealing with the hydrosalpinx]. Zhonghua Fu Chan Ke Za Zhi. 2008 Jun;43(6):414-7. Chinese. PubMed 19035133 ↗
  • Xu B, Zhang Q, Zhao J, Wang Y, Xu D, Li Y. Pregnancy outcome of in vitro fertilization after Essure and laparoscopic management of hydrosalpinx: a systematic review and meta-analysis. Fertil Steril. 2017 Jul;108(1):84-95.e5. doi: 10.1016/j.fertnstert.2017.05.005. Epub 2017 Jun 1. PubMed 28579408 ↗
  • Arora P, Arora RS, Cahill D. Essure((R)) for management of hydrosalpinx prior to in vitro fertilisation-a systematic review and pooled analysis. BJOG. 2014 Apr;121(5):527-36. doi: 10.1111/1471-0528.12533. Epub 2014 Jan 3. PubMed 24393165 ↗
  • Johnson N, van Voorst S, Sowter MC, Strandell A, Mol BW. Surgical treatment for tubal disease in women due to undergo in vitro fertilisation. Cochrane Database Syst Rev. 2010 Jan 20;2010(1):CD002125. doi: 10.1002/14651858.CD002125.pub3. PubMed 20091531 ↗

Individual participant data

Plan to share: Yes — Individual participant data that underlie the results after deidentification (text, tables, figures, and appendices) and study protocol will be shared. Data will be available when beginning 3 months and ending 5 years following article publication. To achieve aims in the approved proposal, researchers who provide a methodologically sound proposal will be shared with.Data will be made available by the following way. Proposals should be directed to lihe198900@163.com. And data are available for 5 years at a third party website (link to be included after the article publication).

Supporting information: Study protocol, Sap

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 24, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03521128
Lead sponsor
ShangHai Ji Ai Genetics & IVF Institute
Responsible party
Sponsor
First posted
May 11, 2018
Start date
May 5, 2018
Primary completion
May 2020 (estimated)
Completion
Jul 2029 (estimated)
Last update
Sep 24, 2019

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion